Thymogen

1. Overview

Thymogen (L-Glu-L-Trp, EW) is a synthetic dipeptide immunomodulator with a molecular weight of 333.34 g/mol (C16H19N3O5; CAS 38101-59-6). It was developed through the joint research of scientists from Moscow and Leningrad (now Saint Petersburg) under the leadership of Vladimir Khavinson in the late 1980s, and has been in clinical use in the Russian Federation since 1990 [4] [9].

Thymogen was identified as the principal active component of Thymalin, the bovine thymic extract that was the first preparation in Khavinson's peptide bioregulator program. Through reversed-phase HPLC fractionation of Thymalin, the EW dipeptide was isolated and shown to reproduce the immunomodulatory activity of the crude thymic extract [4] [15]. It represents the transition in Khavinson's research program from complex biological extracts to defined synthetic peptides.

Among the Khavinson peptide bioregulators, Thymogen holds a distinctive status: it is one of six preparations that have achieved pharmaceutical registration in Russia, alongside Thymalin, Cortexin, Retinalamin, Prostatilen, and Epithalamin [9] [10]. It is registered in three formulations -- intramuscular injection solution (100 mcg/mL), metered-dose nasal spray (25 mcg/dose), and 0.05% topical cream -- making it the most versatile of the registered Khavinson peptides in terms of delivery routes [3] [9].

Thymogen is also notable for a remarkable property of its enantiomer: the D-form of the same dipeptide (D-Glu-D-Trp), marketed as Thymodepressin, exhibits the exact opposite biological activity -- immunosuppression rather than immunostimulation. This represents one of the first documented examples of reciprocal chiral pharmacology in peptide therapeutics [3] [16].

Thymogen is not approved by the FDA, EMA, or any Western regulatory agency. It is also known in the Western research literature as Oglufanide or IM-862.

Sequence

Glu-Trp (EW)

Molecular Weight

333.34 g/mol

Chemical Formula

C16H19N3O5

CAS Number

38101-59-6

Russian Registration

IM injection (LS-002304), nasal spray (P N002408/01), cream 0.05% (LSR-003508/07)

Mechanism

T-cell differentiation activator; cyclic nucleotide modulator (cAMP/cGMP); neutrophil chemotaxis/phagocytosis enhancer

Routes Approved

Intramuscular injection (100 mcg/mL), nasal spray (25 mcg/dose), topical cream (0.05%)

FDA/EMA Status

Not approved by any Western regulatory agency

2. Molecular Pharmacology

T-Cell Differentiation and Immune Reconstitution

Thymogen activates T-cell differentiation by enhancing the thymic education process, promoting maturation of pre-T cells into functional T lymphocytes [4]. Specific immunological effects include:

• Normalization of the concentration and ratio of T-lymphocyte subsets (CD3+, CD4+, CD8+)
• Enhancement of T-cell recognition of peptide-MHC complexes
• Stimulation of immunoglobulin production (IgA, IgG, IgE, IgM)
• Increase in secretory IgA (sIgA) content in the upper respiratory tract (nasal spray formulation)
• Enhancement of neutrophilic chemotaxis and phagocytosis [4] [15]

Cyclic Nucleotide Modulation

A distinctive feature of Thymogen's mechanism is its ability to modulate intracellular cyclic nucleotide balance, specifically the ratio of cAMP to cGMP [4]. This modulation affects downstream signaling cascades governing immune cell activation, differentiation, and cytokine production. The cAMP/cGMP ratio is a key determinant of the balance between Th1 and Th2 immune responses.

Bidirectional Immune Regulation

Thymogen functions as a true immunomodulator rather than a simple immunostimulant: it strengthens weakened immunity while reducing an inadequately high immune response [4] [9]. This bidirectional activity distinguishes it from pure immunostimulants and suggests engagement with homeostatic regulatory mechanisms rather than unidirectional activation of immune pathways.

Histone Binding and Epigenetic Effects

The EW peptide demonstrates energetically favorable binding to histone H1/3 in molecular modeling studies, altering chromatin conformation and gene accessibility [5]. This proposed epigenetic mechanism is consistent with the broader Khavinson bioregulator framework of direct peptide-DNA/histone interaction as a basis for gene expression modulation [12].

Anti-Aging and Anti-Carcinogenic Properties

In the landmark 12-month rat study by Anisimov and Khavinson, subcutaneous L-Glu-L-Trp (5 mcg/rat, 5 times weekly) produced significant anti-aging and anti-carcinogenic effects [1]:

• Total tumor incidence reduced 1.5-fold
• Malignant tumor incidence reduced 1.7-fold
• Hematopoietic malignancy incidence reduced 3.4-fold
• Age-related changes in estrous cycle function slowed
• Body weight parameters normalized

3. Chiral Pharmacology: Thymogen vs. Thymodepressin

One of the most scientifically interesting aspects of Thymogen is the discovery that its D-enantiomer exhibits opposite biological activity [3] [16]:

L-Glu-L-Trp (Thymogen): Immunostimulant. Enhances T-cell differentiation, increases lymphocyte proliferation, promotes antibody production, activates phagocytosis.

D-Glu-D-Trp (Thymodepressin): Immunosuppressant. Inhibits T-cell proliferation, suppresses lymphocyte activation, reduces immune hyperactivity.

Thymodepressin is separately registered in Russia and used clinically for treatment of autoimmune conditions including psoriasis, atopic dermatitis, lichen planus, and autoimmune cytopenias [3] [16]. This reciprocal activity of enantiomers -- where the mirror-image molecule produces the exact opposite pharmacological effect -- is extremely rare in pharmacology and has been termed "reciprocal chiral activity" by Deigin and colleagues [3].

The mechanistic basis for this chirality-dependent reversal is not fully understood. One hypothesis is that the L-form and D-form bind to the same molecular targets (DNA, histones, or receptors) in opposite orientations, producing opposing conformational effects [3]. Another possibility involves differential recognition by peptidases: the L-form is rapidly hydrolyzed by cellular dipeptidases, generating a transient signaling peak, while the D-form resists proteolysis and produces sustained receptor occupancy with different downstream consequences [17].

4. Formulations and Routes of Administration

Thymogen is unique among Khavinson's registered peptides in being available in three distinct formulations:

Intramuscular Injection

The injectable form contains 100 mcg/mL Thymogen in isotonic saline. It is used for more severe immunodeficiency states, post-chemotherapy immune recovery, and acute infectious conditions. Standard dosing is 100-1000 mcg (1-10 mL) daily for 3-10 days [4] [10].

Nasal Spray

The metered-dose nasal spray delivers 25 mcg per spray actuation. It is the most widely used formulation, particularly for prevention and treatment of upper respiratory tract infections. The nasal route provides direct delivery to the respiratory mucosal immune system, where Thymogen increases secretory IgA (sIgA) levels [2] [19]. Dosing for adults is 1 spray (25 mcg) in each nostril twice daily; pediatric doses are age-adjusted [2].

Topical Cream

A 0.05% cream formulation is used for dermatological conditions and wound healing applications. Clinical experience includes use in post-surgical wound healing and treatment of skin infections [9].

5. Researched Applications

Acute Respiratory Infections

The strongest clinical evidence for Thymogen involves prevention and treatment of acute respiratory viral infections (ARVI). A study in military personnel demonstrated that both intranasal and subcutaneous Thymogen significantly reduced morbidity rate, severity, and duration of acute respiratory infections [2]. In vitro studies confirmed direct virucidal activity of the nasal spray formulation against respiratory syncytial virus (RSV) and parainfluenza virus [19].

Immunodeficiency States

In Russian clinical practice, Thymogen is indicated for treatment of immunodeficiency conditions arising from various causes [4] [9] [10]:

• Post-chemotherapy and post-radiation therapy immune suppression
• Chronic and recurrent infections
• Post-surgical immune recovery
• Age-related immune decline
• Suppression of regeneration and hematopoiesis

Anti-Aging (Preclinical)

The 12-month rat study demonstrated that Thymogen slows biological aging as measured by estrous cycle function, body weight dynamics, and spontaneous carcinogenesis rates [1]. Combined with its parent compound Thymalin's clinical mortality reduction data in elderly humans [6], these findings position the EW dipeptide as a candidate geroprotective agent, though human anti-aging clinical trials of Thymogen itself have not been published.

COVID-19 (as Thymalin Component)

While Thymogen itself was not tested separately in COVID-19, its parent compound Thymalin (of which EW is the principal active component) demonstrated halved hospital mortality in elderly COVID-19 patients in an RCT [7]. The immunomodulatory mechanism of Thymalin's clinical efficacy is attributed in substantial part to the EW dipeptide [15].

Autoimmune Conditions (D-enantiomer)

The D-form Thymodepressin is used for autoimmune conditions including psoriasis, atopic dermatitis, lichen planus, and autoimmune cytopenias [3] [16]. While this application uses the opposite enantiomer, it demonstrates the pharmacological significance of the Glu-Trp dipeptide scaffold in immune regulation.

6. Clinical Evidence

Approved Clinical Use: Thymogen has been in registered clinical use in Russia since 1990, with decades of post-market clinical experience [9]. However, formal post-marketing surveillance data meeting Western regulatory standards have not been published.

Controlled Clinical Studies: The military ARVI study demonstrated clinico-epidemiological efficacy for respiratory infection prevention and treatment [2]. Additional clinical studies referenced in Russian-language reviews support efficacy in immunodeficiency states [10].

Animal Studies: The 12-month rat study by Anisimov and Khavinson provides well-controlled preclinical evidence for anti-aging and anti-carcinogenic effects [1].

In Vitro Studies: Direct virucidal activity against respiratory viruses [19], immunomodulatory effects in cell culture [13], and histone binding studies [5] support the molecular mechanisms.

No large-scale, multicenter, double-blind Phase III trials conducted by independent research groups have been published. No clinical trials are registered on ClinicalTrials.gov.

7. Dosing in Published Research

The following doses have been reported in published research and approved clinical protocols. These are not recommendations and should not be interpreted as therapeutic guidance outside the context of Russian clinical practice where Thymogen is a registered pharmaceutical.

8. Safety and Side Effects

Thymogen has an extensive safety record in Russian clinical practice spanning over three decades of registered use [4] [9]. Published literature consistently describes it as well-tolerated with minimal reported adverse effects.

In the 12-month rat study, no significant adverse effects were documented despite sustained administration (5 mcg/rat, 5 times weekly for a full year) [1]. The nasal spray formulation has been used in children as young as 1 year old according to approved Russian prescribing information, suggesting a favorable pediatric safety profile based on Russian regulatory assessment.

Important caveats:

• No systematic toxicology studies meeting ICH/FDA regulatory standards have been published in Western literature.
• As an immunomodulator, use in patients with autoimmune conditions requires caution (note that the D-enantiomer is the preparation used for autoimmune disease).
• Drug interaction studies with standard Western pharmaceuticals are absent.
• Long-term safety data from controlled studies (as distinguished from post-market experience) are limited.
• Pharmacokinetic data (oral/nasal bioavailability, plasma half-life, metabolism) meeting Western standards are not available.

9. Relationship to Thymalin

Thymogen is the defined synthetic dipeptide derived from Thymalin, the crude bovine thymic extract. Key relationships:

• Thymalin is a multi-component biological extract containing EW (Thymogen), KE (Vilon), EDP (Crystagen), and other peptide fractions [15].
• Thymogen reproduces the principal immunomodulatory activity of Thymalin as a single defined molecule [4].
• Thymalin has more extensive clinical data, including the COVID-19 RCT and elderly mortality studies, but as a complex extract it cannot be reduced to a single molecular entity [7].
• Thymogen offers the advantages of defined composition, batch consistency, and synthetic production over the biological extract [4].
• Both preparations are registered pharmaceuticals in Russia, with Thymalin having been approved earlier (1982 vs. 1990) [9].

10. Limitations and Transparency

• While registered in Russia since 1990, Thymogen has not been evaluated by any Western regulatory agency.
• Most clinical evidence exists in Russian-language literature not easily accessible to Western researchers.
• Independent replication of clinical findings by non-Russian research groups is essentially absent.
• The proposed epigenetic mechanism (direct peptide-histone binding) has been demonstrated through molecular modeling but not confirmed by structural biology methods.
• Formal pharmacokinetic studies meeting international standards are not published.
• The relationship between the L-form (immunostimulant) and D-form (immunosuppressant) activity raises important mechanistic questions that remain incompletely resolved.

11. Related Peptides

See also: Thymalin, Vilon, Thymosin Alpha-1, Epithalon

12. References

1. [1] Anisimov VN, Khavinson VK, Morozov VG (2000). Immunomodulatory synthetic dipeptide L-Glu-L-Trp slows down aging and inhibits spontaneous carcinogenesis in rats. Biogerontology. DOI PubMed
2. [2] Smirnov VS et al. (1993). The clinico-epidemiological efficacy of thymogen in acute respiratory viral infections in a military collective. Voen Med Zh. PubMed
3. [3] Deigin VI, Antipova NV, Shubina IZ (2024). The first reciprocal activities of chiral peptide pharmaceuticals: Thymogen and Thymodepressin, as examples. Int J Mol Sci. DOI PubMed
4. [4] Morozov VG, Khavinson VK (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. DOI PubMed
5. [5] Khavinson VK, Tendler SM, Vanyushin BF, Kasyanenko NA, Kvetnoy IM, Linkova NS, Ashapkin VV, Polyakova VO, Basharina VS, Bernadotte A (2014). Peptide regulation of gene expression and protein synthesis in bronchial epithelium. Lung. DOI PubMed
6. [6] Khavinson VK, Morozov VG (2003). Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett. PubMed
7. [7] Khavinson VK, Linkova NS, Kvetnoy IM, Kvetnaia TV, Polyakova VO, Korf HW (2021). Peptide drug Thymalin regulates immune status in severe COVID-19 older patients. Adv Gerontol. DOI PubMed
8. [8] Khavinson VK (2002). Peptides and ageing. Neuro Endocrinol Lett. PubMed
9. [9] Khavinson VK (2020). Peptide medicines: past, present, future. Klin Med (Mosk). PubMed
10. [10] Khavinson VK, Kuznik BI, Ryzhak GA (2013). Peptide bioregulators: a new class of geroprotectors. Report 2. Clinical studies results. Adv Gerontol. PubMed
11. [11] Anisimov VN, Khavinson VK (2010). Peptide bioregulation of aging: results and prospects. Biogerontology. DOI PubMed
12. [12] Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR (2021). Peptide regulation of gene expression: a systematic review. Molecules. DOI PubMed
13. [13] Kuznik BI, Linkova NS, Khavinson VK (2022). Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int J Mol Sci. DOI PubMed
14. [14] Khavinson VK, Linkova NS, Kvetnoy IM (2020). Peptides: prospects for use in the treatment of COVID-19. Molecules. DOI PubMed
15. [15] Khavinson VK, Linkova NS, Dyatlova AS, Kuznik BI, Umnov RS (2021). The use of Thymalin for immunocorrection and molecular aspects of biological activity. Biol Bull Rev. DOI PubMed
16. [16] Deigin VI et al. (2021). Thymodepressin -- unforeseen immunosuppressor. Int J Mol Sci. PubMed
17. [17] Deigin VI et al. (2023). Advancement from small peptide pharmaceuticals to orally active piperazine-2,5-dion-based cyclopeptides. Int J Mol Sci. PubMed
18. [18] Fedoreyeva LI, Kireev II, Khavinson VK, Vanyushin BF (2011). Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). DOI PubMed
19. [19] Smirnov VS et al. (2024). Virucidal activity of the drug Thymogen, a nasal dosed spray, against human respiratory viruses in vitro. Antibiot Khimioter. PubMed